Boothbay Fund Management LLC raised its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 30.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,287,767 shares of the company's stock after purchasing an additional 304,065 shares during the quarter. Boothbay Fund Management LLC owned 2.03% of Evolus worth $14,217,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in EOLS. KBC Group NV purchased a new stake in Evolus in the 4th quarter worth about $49,000. IFP Advisors Inc grew its stake in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock worth $52,000 after acquiring an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS bought a new position in Evolus in the 4th quarter worth about $106,000. Quantbot Technologies LP bought a new position in Evolus in the 4th quarter worth about $118,000. Finally, Tradition Wealth Management LLC grew its stake in Evolus by 18.2% in the 4th quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company's stock worth $144,000 after acquiring an additional 2,000 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of brokerages have commented on EOLS. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Evolus in a research note on Wednesday, April 9th. HC Wainwright restated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research note on Thursday, April 10th. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, BTIG Research began coverage on shares of Evolus in a research note on Thursday, April 17th. They issued a "buy" rating and a $21.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $23.75.
Check Out Our Latest Research Report on EOLS
Insider Activity
In other Evolus news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total value of $60,147.36. Following the completion of the sale, the chief marketing officer now directly owns 95,671 shares in the company, valued at $1,268,597.46. This trade represents a 4.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Rui Avelar sold 27,904 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the completion of the sale, the insider now owns 362,467 shares of the company's stock, valued at approximately $4,806,312.42. This trade represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 60,575 shares of company stock worth $794,369. Corporate insiders own 6.10% of the company's stock.
Evolus Stock Up 0.4 %
Shares of NASDAQ EOLS traded up $0.05 during midday trading on Thursday, reaching $11.45. 135,716 shares of the company's stock traded hands, compared to its average volume of 665,220. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock's 50 day simple moving average is $12.07 and its 200-day simple moving average is $12.84. Evolus, Inc. has a one year low of $8.67 and a one year high of $17.82. The company has a market cap of $728.07 million, a price-to-earnings ratio of -12.60 and a beta of 0.97.
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Articles
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
